Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation
Sign Up to like & getrecommendations! Published in 2017 at "Yonsei Medical Journal"
DOI: 10.3349/ymj.2017.58.3.679
Abstract: www.eymj.org To the Editor: For decades, the human leukocyte antigen (HLA) complex has been considered the primary target of antibody-mediated rejection (AMR), and treatment strategies have mainly focused on anti-HLA antibodies. Recently, other antibodies potentially… read more here.
Keywords: at1r antibodies; anti at1r; anti hla; anti ... See more keywords